Luis Soro1, Cynthia Bartus2, Stephen Purcell3. 1. Department of Dermatology, Lehigh Valley Health Network and Philadelphia College of Osteopathic Medicine, Allentown, Pennsylvania, and Philadelphia, Pennsylvania; 2. Department of Dermatology, Lehigh Valley Health Network; 3. Department of Dermatology, Lehigh Valley Health Network and Philadelphia College of Osteopathic Medicine, Allentown, Pennsylvania, and Philadelphia, Pennsylvania.
Abstract
OBJECTIVE: Review the pathogenesis of recessive dystrophic epidermolysis bullosa and provide an update on research currently underway that is aimed at treating and potentially curing this severe skin disorder. DESIGN: Review article. SETTING: Private practice and large teaching hospital. PARTICIPANTS: None. MEASUREMENTS: N/A. RESULTS: Currently, patients with recessive dystrophic epidermolysis bullosa are managed with only supportive care. However, there are several promising new treatment avenues that may help patients in the future. These include gene therapy, cell therapy, and protein-based therapy. Each approach offers distinct advantages and disadvantages. CONCLUSIONS: The advances in understanding the molecular basis for epidermolysis bullosa over the last few decades has led to significant progress in devising new treatment options. Though many of these approaches remain several years away from regular implementation, it is an exciting time for research in the field.
OBJECTIVE: Review the pathogenesis of recessive dystrophic epidermolysis bullosa and provide an update on research currently underway that is aimed at treating and potentially curing this severe skin disorder. DESIGN: Review article. SETTING: Private practice and large teaching hospital. PARTICIPANTS: None. MEASUREMENTS: N/A. RESULTS: Currently, patients with recessive dystrophic epidermolysis bullosa are managed with only supportive care. However, there are several promising new treatment avenues that may help patients in the future. These include gene therapy, cell therapy, and protein-based therapy. Each approach offers distinct advantages and disadvantages. CONCLUSIONS: The advances in understanding the molecular basis for epidermolysis bullosa over the last few decades has led to significant progress in devising new treatment options. Though many of these approaches remain several years away from regular implementation, it is an exciting time for research in the field.
Authors: John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar Journal: N Engl J Med Date: 2010-08-12 Impact factor: 91.245
Authors: Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath Journal: J Invest Dermatol Date: 2008-04-03 Impact factor: 8.551
Authors: David T Woodley; Gerald G Krueger; Cynthia M Jorgensen; Janet A Fairley; Tom Atha; Yi Huang; Lawrence Chan; Douglas R Keene; Mei Chen Journal: J Invest Dermatol Date: 2003-11 Impact factor: 8.551
Authors: I I Ryumina; K V Goryunov; D N Silachev; Yu A Shevtsova; V A Babenko; N M Marycheva; Yu Yu Kotalevskaya; V V Zubkov; G T Zubkov Journal: Bull Exp Biol Med Date: 2021-05-29 Impact factor: 0.804
Authors: Fozia Fozia; Rubina Nazli; May Mohammed Alrashed; Hazem K Ghneim; Zia Ul Haq; Musarrat Jabeen; Sher Alam Khan; Ijaz Ahmad; Mohammed Bourhia; Mourad A M Aboul-Soud Journal: Diagnostics (Basel) Date: 2022-06-23
Authors: James A Feinstein; Anna L Bruckner; Benjamin Chastek; Amy Anderson; Juan Roman Journal: Orphanet J Rare Dis Date: 2022-09-29 Impact factor: 4.303
Authors: Patricia Peking; Ulrich Koller; Blanca Duarte; Rodolfo Murillas; Susanne Wolf; Tobias Maetzig; Michael Rothe; Thomas Kocher; Marta García; Gabriele Brachtl; Axel Schambach; Fernando Larcher; Julia Reichelt; Johann W Bauer; Eva M Murauer Journal: Nucleic Acids Res Date: 2017-09-29 Impact factor: 16.971